ID Recombinant Ricin Toxin A-Chain Vaccine RVEc™ — 3-Dose Primary Series With Boost

Ricin Poisoning Clinical Trial

Official title:

Phase 1b Escalating Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) Administered Intradermally to Healthy Adults as a 3-Dose Primary Series and Booster

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02386150
• Other study ID #: S-14-05
• Secondary ID: FY14-09
• Status: Withdrawn
• Phase: Phase 1
• Start date: October 2017
• Est. completion date: December 2018

Study information

• Verified date: December 2019
• Source: U.S. Army Medical Research and Development Command
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study seeks to determine the safety and immunogenicity of a series of 3 primary vaccinations and a booster vaccination of Recombinant ricin toxin A-chain 1-33/44-198 (rRTA 1-33/44-198) vaccine (RVEc) at 10 or 20 μg intradermally (ID). This study is evaluating if RVEc will display an acceptable safety profile as determined by adverse event (AE) data and if RVEc will elicit anti-ricin antibody titers and ricin toxin-neutralizing antibodies in vaccine recipients.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2018
• Est. primary completion date: December 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Study participants must read and sign an approved informed consent.

• Study participants must be at least 18 years old at time of screening and no older than 50 years old at time of first study vaccination.

• Participants must weigh at least 110 pounds at time of screening.

• Participants must be in good health as judged from medical history, physical examination, electrocardiogram, chest x-ray, hematology, clinical chemistries, urinalysis, hepatitis serology, and human immunodeficiency virus (HIV) antibody test and must be medically cleared for participation by an investigator.

• Females of childbearing potential must have a negative pregnancy test on screening and the morning of each vaccination prior to receipt of the vaccine and must agree to use a highly effective method of birth control from screening through 3 months following last study vaccination. A highly effective method of birth control is defined as one with a failure rate of less than 1% per year. Acceptable birth control methods that meet this criterion include hormonal implants and injectables, combined oral contraceptives, intrauterine devices, female sterilization (tubal ligation), sexual abstinence, or a vasectomized partner.

• Female participants must also agree not to breastfeed from screening through 3 months following last study vaccination.

• Study participants must be willing to return for all follow-up visits.

• Study participants must agree to report any adverse events (AE) that may or may not be associated with administration of the investigational product through the duration of study participation.

• Study participants must agree to abstain from excessive exercise (more than the usual routine) and excessive alcohol consumption (exceeds 2 drinks for males or exceeds 1 drink for females daily or binge drinking) for the duration of study participation.

Exclusion Criteria:

• Acute or chronic medical conditions or immunodeficiency from a medical condition or medical treatment, medications, or dietary supplements that, in the investigator's opinion, would impair the subject's ability to respond to vaccination. Use of corticosteroids, other than inhaled or topical corticosteroids or eye drops, will not be permitted.

• Severe hypersensitivity to any vaccine.

• History of asthma, chronic obstructive pulmonary disease, or other current/residual diseases of the lungs.

• Clinically significant abnormal laboratory tests. (Normal reference ranges are determined by the local clinical laboratory.)

• Current smoker, to include use of electronic cigarettes.

• Any known allergies to sodium succinate, Polysorbate 20 (a detergent), Alhydrogel, or kanamycin.

• Receipt of any vaccine or investigational product within 30 days before or after vaccination with RVEc (the only exception is the inactivated influenza vaccine that can be received at least 30 days after RVEc Dose 3 or 4).

• Creatine phosphokinase levels that are consistently elevated more than 2 × normal.

• Previous vaccination with RVEc or any other ricin vaccine candidate by any route.

Related Conditions & MeSH terms

• Poisoning
• Ricin Poisoning

Intervention

Biological:
• RVEc
The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial

Locations

Country	Name	City	State
United States	Department of Clinical Research, USAMRIID	Fort Deterick	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
U.S. Army Medical Research and Development Command	United States Army Medical Research Institute of Infectious Diseases

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of vaccinated subjects without adverse events by Day 730	Adverse events will be evaluated for subjects in the assessment population on vaccination days and at follow-up time points.	Day 730
Primary	Percentage of vaccinated subjects with adverse events by Day 730	Adverse events will be evaluated for subjects in the assessment population on vaccination days and at follow-up time points.	Day 730
Primary	Percentage of vaccinated subjects with any severity of local reactions (Grades 1-4) by Day 730	Adverse events will be evaluated for subjects in the assessment population on vaccination days and at follow-up time points.	Day 730
Primary	Percentage of vaccinated subjects with system reactions of any severity (Grades 1-4) by Day 730	Adverse events will be evaluated for subjects in the assessment population on vaccination days and at follow-up time points.	Day 730
Primary	Percentage of vaccinated subjects with generalized allergic reactions by Day 730	Adverse events will be evaluated for subjects in the assessment population on vaccination days and at follow-up time points.	Day 730
Primary	Percentage of vaccinated subjects with each adverse event by Day 730	Adverse events will be evaluated for subjects in the assessment population on vaccination days and at follow-up time points.	Day 730
Secondary	Total anti-ricin immunoglobulin G (IgG) antibody titers as determined by ELISA		Days 0, 14, 28, 42, 56, 106, 120, 134, 180, 270, 365, 379, 393, 455, 555, 730
Secondary	Anti-ricin toxin-neutralizing antibody titers as determined by the colorimetric toxin neutralization assay (TNA)		Days 0, 14, 28, 42, 56, 106, 120, 134, 180, 270, 365, 379, 393, 455, 555, 730